ADGRG1 and acute myeloid leukemia: These data are consistent with a recent report on bone marrow T cell signatures [21] and collectively suggest that ADGRG1 expression of circulating cytotoxic T cells also is a potential biomarker of effective GvL responses in AML patients following alloHSCT.